---
document_datetime: 2023-09-21 21:53:46
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/triumeq-epar-all-authorised-presentations_en.pdf
document_name: triumeq-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9813316
conversion_datetime: 2025-12-29 23:12:10.61861
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength                | Pharmaceutical Form   | Route of Administration   | Immediate Packaging             | Pack size                       |
|------------------|-------------------|-------------------------|-----------------------|---------------------------|---------------------------------|---------------------------------|
| EU/1/14/940/001  | Triumeq           | 50 mg / 600 mg / 300 mg | Film-coated tablet    | Oral use                  | Bottle (HDPE)                   | 30 tablets                      |
| EU/1/14/940/002  | Triumeq           | 50 mg / 600 mg / 300 mg | Film-coated tablet    | Oral use                  | Bottle (HDPE)                   | 90 (3 x 30) tablets (multipack) |
| EU/1/14/940/003  | Triumeq           | 5 mg / 60 mg / 30 mg    | Dispersible tablet    | Oral use                  | Bottle (HDPE) + 1 measuring cup | 90 tablets                      |